Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers: Head&Neck (H&N), Neuroendocrine Tumors (NET) and Soft Tissue Sarcoma (STS).

NCT04166006 is registered in ClinicalTrials.gov with Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS as lead sponsor.

NCT NCT04166006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04166006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers: Head&Neck (H&N), Neuroendocrine Tumors (NET) and Soft Tissue Sarcoma (STS).
Lead sponsor
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase
Phase 2
Overall status
Recruiting
Start date
December 12, 2019
Completion date
December 31, 2031
Enrollment
51 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head neck tumors, neuroendocrine tumors, rare cancer, soft tissue sarcoma, vaccination